Table 3 Ordinary least squares (OLS) regression predicting length of therapy
From: Antipsychotic patterns of use in patients with schizophrenia: polypharmacy versus monotherapy
95% Confidence interval | ||||
|---|---|---|---|---|
Covariate a | Coef. | (lower – upper) | p-Value | |
Polypharmacy (reference = monotherapy) | −106.638 | (−117.179 – −96.096) | <.001 | |
Female (reference = male) | −1.700 | (−10.914 – 7.514) | .718 | |
Age | 1.582 | (1.198 – 1.965) | <.001 | |
Number of post-index psychiatric comorbidities of interest (reference = 0) | ||||
One | −9.402 | (−19.946 – 1.142) | .081 | |
Two | −38.278 | (−52.526 – −24.031) | <.001 | |
Three or more | −67.391 | (−87.620 – −47.163) | <.001 | |
Number of psychiatric medications post-index (reference = 0) | ||||
One | −4.376 | (−17.546 – 8.794) | .515 | |
Two or more | −12.682 | (−25.211 – −0.153) | .047 | |
Number of somatic medications post-index (reference = 0) | ||||
One | 20.108 | (8.237 – 31.980) | .001 | |
Two or more | 13.279 | (−1.724 – 28.283) | .083 | |
Constant | 218.211 | (197.930 – 238.492) | <.001 | |
R 2 | 0.148 | |||